SOURCE: DSM N.V.

December 17, 2010 01:23 ET

DSM announces reversal of impairment

HEERLEN, NETHERLANDS--(Marketwire - December 17, 2010) - Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that - in accordance with applicable IFRS accounting standards - the remaining impairment of approximately EUR 55 million for DSM Anti-Infectives will be reversed in Q4 2010. This reversal of impairment will be reported as an exceptional item in DSM's Q4 2010 results, which will be published on 23 February 2011.

This reversal is caused by the improved business outlook for DSM Anti- Infectives related to the new strategy Leveraging partnerships for growth in addition to own initiatives like the new 6-APA plant in China. This reversal is a non- cash item.

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about EUR8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com.


Press release-pdf: http://hugin.info/130663/R/1473553/409934.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: DSM N.V. via Thomson Reuters ONE

[HUG#1473553]

Contact Information

  • For more information:
    DSM Corporate Communications
    Herman Betten
    tel. +31 (0) 45 5782017
    fax +31 (0) 45 5740680
    e-mail Email Contact

    DSM Investor Relations
    Hans Vossen
    tel. +31 (0) 45 5782864
    fax +31 (0) 10 4590275
    e-mail Email Contact